Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
32.37
USD
|
+2.44%
|
|
-6.77%
|
-21.36%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,574
|
4,090
|
4,343
|
1,821
|
2,799
|
2,211
|
-
|
-
|
Enterprise Value (EV)
1 |
1,567
|
3,505
|
4,237
|
611.1
|
1,539
|
1,398
|
1,767
|
1,835
|
P/E ratio
|
-19.3
x
|
-28.1
x
|
-21.5
x
|
-6.44
x
|
-6.22
x
|
-6.13
x
|
-6.19
x
|
-7.08
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
36.6
x
|
188
x
|
93
x
|
13.9
x
|
35.7
x
|
13.8
x
|
10.2
x
|
7.6
x
|
EV / Revenue
|
36.5
x
|
161
x
|
90.7
x
|
4.65
x
|
19.6
x
|
8.7
x
|
8.14
x
|
6.3
x
|
EV / EBITDA
|
-31.4
x
|
-28.8
x
|
-22.2
x
|
-2.38
x
|
-3.88
x
|
-3.45
x
|
-4.97
x
|
-5.24
x
|
EV / FCF
|
-33.4
x
|
-36.4
x
|
7.64
x
|
-2.18
x
|
-4.39
x
|
-5.29
x
|
-5.35
x
|
-5.85
x
|
FCF Yield
|
-2.99%
|
-2.75%
|
13.1%
|
-45.9%
|
-22.8%
|
-18.9%
|
-18.7%
|
-17.1%
|
Price to Book
|
-
|
-
|
5.57
x
|
3.22
x
|
3.46
x
|
8.78
x
|
-30.9
x
|
114
x
|
Nbr of stocks (in thousands)
|
38,304
|
48,158
|
52,872
|
53,228
|
67,999
|
68,308
|
-
|
-
|
Reference price
2 |
41.09
|
84.93
|
82.14
|
34.21
|
41.16
|
32.37
|
32.37
|
32.37
|
Announcement Date
|
3/16/20
|
3/1/21
|
2/28/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
42.98
|
21.8
|
46.7
|
131.4
|
78.5
|
160.6
|
216.9
|
291.1
|
EBITDA
1 |
-49.96
|
-121.7
|
-190.5
|
-256.9
|
-396.7
|
-405
|
-355.2
|
-350.2
|
EBIT
1 |
-51.52
|
-124.9
|
-195.3
|
-263.2
|
-401.5
|
-378.2
|
-368.1
|
-344.3
|
Operating Margin
|
-119.89%
|
-572.69%
|
-418.2%
|
-200.3%
|
-511.46%
|
-235.5%
|
-169.69%
|
-118.27%
|
Earnings before Tax (EBT)
1 |
-70.29
|
-119.3
|
-191
|
-261.6
|
-363.9
|
-345.6
|
-354.8
|
-333.8
|
Net income
1 |
-70.29
|
-119.3
|
-191
|
-282.5
|
-367.3
|
-327.3
|
-336.2
|
-318.7
|
Net margin
|
-163.56%
|
-547.35%
|
-408.99%
|
-214.99%
|
-467.9%
|
-203.82%
|
-154.97%
|
-109.48%
|
EPS
2 |
-2.130
|
-3.020
|
-3.820
|
-5.310
|
-6.620
|
-5.284
|
-5.228
|
-4.570
|
Free Cash Flow
1 |
-46.87
|
-96.2
|
554.7
|
-280.3
|
-350.7
|
-264.2
|
-330.3
|
-313.8
|
FCF margin
|
-109.06%
|
-441.27%
|
1,187.79%
|
-213.32%
|
-446.75%
|
-164.53%
|
-152.28%
|
-107.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/1/21
|
2/28/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
9.285
|
26.3
|
24.2
|
31.3
|
30.3
|
38
|
32.5
|
54.5
|
34.6
|
-43.1
|
34.85
|
56.13
|
34.19
|
40.62
|
28.11
|
EBITDA
1 |
-46.13
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-164.1
|
-61.87
|
-62.94
|
-64.01
|
-
|
-
|
EBIT
1 |
-47.33
|
-54.4
|
-60
|
-68.3
|
-67.2
|
-75.4
|
-87.7
|
-74.6
|
-73.9
|
-165.3
|
-97.86
|
-90.9
|
-104.6
|
-92.59
|
-136.3
|
Operating Margin
|
-509.77%
|
-206.84%
|
-247.93%
|
-218.21%
|
-221.78%
|
-198.42%
|
-269.85%
|
-136.88%
|
-213.58%
|
383.53%
|
-280.82%
|
-161.94%
|
-305.95%
|
-227.96%
|
-484.81%
|
Earnings before Tax (EBT)
1 |
-46.75
|
-53
|
-58.9
|
-66.6
|
-64
|
-72.1
|
-81.2
|
-65.6
|
-63.9
|
-153.2
|
-89.13
|
-77.29
|
-94.65
|
-101.1
|
-125.5
|
Net income
1 |
-46.75
|
-53
|
-63.4
|
-70
|
-66.2
|
-82.9
|
-81.9
|
-66.6
|
-64
|
-154.8
|
-91.09
|
-71.53
|
-97.41
|
-77.33
|
-125.5
|
Net margin
|
-503.53%
|
-201.52%
|
-261.98%
|
-223.64%
|
-218.48%
|
-218.16%
|
-252%
|
-122.2%
|
-184.97%
|
359.16%
|
-261.41%
|
-127.43%
|
-284.9%
|
-190.4%
|
-446.52%
|
EPS
2 |
-0.9400
|
-1.000
|
-1.200
|
-1.320
|
-1.240
|
-1.560
|
-1.540
|
-1.250
|
-1.180
|
-2.530
|
-1.350
|
-0.9732
|
-1.441
|
-1.399
|
-1.593
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
2/28/22
|
5/5/22
|
8/4/22
|
11/8/22
|
2/23/23
|
5/5/23
|
8/8/23
|
11/7/23
|
2/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
7.21
|
585
|
106
|
1,210
|
1,260
|
814
|
444
|
376
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-46.9
|
-96.2
|
555
|
-280
|
-351
|
-264
|
-330
|
-314
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-26.8%
|
-42%
|
-60%
|
-85.2%
|
-49%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
14.70
|
10.60
|
11.90
|
3.690
|
-1.050
|
0.2800
|
Cash Flow per Share
2 |
-
|
-
|
11.20
|
-5.140
|
-6.270
|
0.5200
|
0.6200
|
-
|
Capex
1 |
6.24
|
6.45
|
4.7
|
6.8
|
2.9
|
8.62
|
12.9
|
18.2
|
Capex / Sales
|
14.53%
|
29.57%
|
10.06%
|
5.18%
|
3.69%
|
5.37%
|
5.93%
|
6.25%
|
Announcement Date
|
3/16/20
|
3/1/21
|
2/28/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
32.37
USD Average target price
70.83
USD Spread / Average Target +118.82% Consensus |
1st Jan change
|
Capi.
|
---|
| -21.36% | 2.21B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|